Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Malcolm J. Moore

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0009-0007-7493-3558; OpenAlex author ID A5003643368. Sources: ClinicalTrials.gov.

Their work

Papers
34 (first author 3, last author 6)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
167
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 5 papers · 2013: 3 papers · 2014: 5 papers · 2015: 2 papers · 2016: 7 papers · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers, 1 trial · 2024: 1 paper · 2025: 2 papers

Papers 34

  1. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  2. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  3. Impact of an Inter-Professional Clinic on Pancreatic Cancer Outcomes: A Retrospective Cohort Study. Co-author DOI 10.3390/curroncol31050194↗
  4. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  5. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of C… Co-author DOI 10.1200/jco.22.02770↗
  6. Altered Gene Expression along the Glycolysis-Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1543↗
  7. NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-0191↗
  8. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Co-author DOI 10.1245/s10434-019-07685-1↗
  9. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adeno… Co-author DOI 10.1002/cncr.31218↗
  10. Exome-Wide Association Study of Pancreatic Cancer Risk. Co-author DOI 10.1053/j.gastro.2017.10.015↗
  11. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Co-author DOI 10.1158/1078-0432.ccr-17-2994↗
  12. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2016.3916↗
  13. A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer. Last author DOI 10.1007/s00280-016-3102-y↗
  14. Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer… Co-author DOI 10.1016/j.pan.2016.08.013↗
  15. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Co-author DOI 10.1038/bjc.2016.212↗
  16. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Co-author DOI 10.1038/bjc.2016.222↗
  17. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have R… Last author DOI 10.1200/jco.2016.68.5776↗
  18. A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3. Co-author DOI 10.1371/journal.pone.0147995↗
  19. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. Co-author DOI 10.21037/jgo.2016.01.03↗
  20. Metformin for pancreatic cancer. First author DOI 10.1016/s1470-2045(15)00029-7↗
  21. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2014.59.7401↗
  22. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Last author DOI 10.1016/j.ejca.2014.04.008↗
  23. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Co-author DOI 10.1038/bjc.2014.418↗
  24. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Co-author DOI 10.1038/bjc.2014.494↗
  25. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Co-author DOI 10.1093/jnci/djt347↗
  26. Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer. Last author DOI 10.3747/co.21.1327↗
  27. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Co-author DOI 10.1002/cncr.28117↗
  28. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Co-author DOI 10.1056/nejmoa1304369↗
  29. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-12-2745↗
  30. A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. First author DOI 10.1007/s10637-010-9611-3↗
  31. A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Last author DOI 10.1007/s10637-011-9673-x↗
  32. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. First author DOI 10.1007/s10637-011-9697-2↗
  33. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. Co-author DOI 10.1007/s11605-011-1781-6↗
  34. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib… Last author DOI 10.1016/j.ejca.2011.10.035↗

Trials 2

  1. Durvalumab and Oleclumab in Resectable PDAC Principal investigator NCT06060405↗
  2. Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients Principal investigator NCT00383760↗

Closest collaborators

The 25 strongest of 167 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Gallinger · 12 shared papers, 2012–2025 · strength 1.05
  2. Jennifer Jane Knox · 7 shared papers, 2016–2025 · strength 0.75
  3. Kyaw Lwin Aung · 5 shared papers, 2015–2025 · strength 0.65
  4. Robert C. Grant · 7 shared papers, 2012–2025 · strength 0.56
  5. Faiyaz Notta · 5 shared papers, 2017–2025 · strength 0.51
  6. Raymond Jang · 3 shared papers, 2024–2025 · strength 0.49
  7. Spring Holter · 6 shared papers, 2012–2025 · strength 0.49
  8. Daniel John Renouf · 7 shared papers, 2012–2025 · strength 0.48
  9. Neesha C. Dhani · 7 shared papers, 2014–2024 · strength 0.47
  10. Grainne Mary O'Kane · 4 shared papers, 2018–2025 · strength 0.46
  11. David William Hedley · 9 shared papers, 2012–2018 · strength 0.40
  12. George Zogopoulos · 3 shared papers, 2018–2025 · strength 0.39
  13. Sandra Elisabeth Fischer · 3 shared papers, 2018–2025 · strength 0.38
  14. Michelle Chan‐Seng‐Yue · 3 shared papers, 2017–2025 · strength 0.37
  15. Erica S. Tsang · 2 shared papers, 2025 · strength 0.33
  16. Joanna M. Karasinska · 3 shared papers, 2019–2025 · strength 0.32
  17. James Thomas Topham · 3 shared papers, 2019–2025 · strength 0.32
  18. David F. Schaeffer · 3 shared papers, 2019–2025 · strength 0.32
  19. David Goldstein · 4 shared papers, 2016–2023 · strength 0.30
  20. Wendy R. Parulekar · 4 shared papers, 2012–2023 · strength 0.29
  21. Alice Chia-Chi Wei · 3 shared papers, 2013–2024 · strength 0.27
  22. Robert A. Wolff · 2 shared papers, 2019–2023 · strength 0.22
  23. Sangeetha N. Kalimuthu · 2 shared papers, 2017–2025 · strength 0.20
  24. Sharlene Gill · 4 shared papers, 2012–2019 · strength 0.18
  25. Abdul Rehman Farooq · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.